Age related macular degeneration 5
disease diseaseOn this page
Also known as age related macular degeneration type 5age-related macular degeneration caused by mutation in ERCC6ARMD5ERCC6 age-related macular degenerationmacular degeneration, age-related, 5macular degeneration, age-related, susceptibility to, 5macular Degeneration, age-related, type 5
Summary
Age related macular degeneration 5 (MONDO:0013409) is a disease with 1 cohort gene.
At a glance
- Cohort genes: 1
- ClinVar variants: 215
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | age related macular degeneration 5 |
| Mondo ID | MONDO:0013409 |
| OMIM | 613761 |
| DOID | DOID:0110028 |
| UMLS | C3151063 |
| MedGen | 462413 |
| Is cancer (heuristic) | no |
Also known as: age related macular degeneration type 5 · age-related macular degeneration caused by mutation in ERCC6 · ARMD5 · ERCC6 age-related macular degeneration · macular degeneration, age-related, 5 · macular degeneration, age-related, susceptibility to, 5 · macular Degeneration, age-related, type 5
Data availability: 215 ClinVar variants.
Disease family
Classification path: disease susceptibility › inherited disease susceptibility › age related macular degeneration, susceptibility to › age related macular degeneration 5
Related subtypes (2): age related macular degeneration 13, age related macular degeneration 15
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
215 retrieved; paginated sample, class counts are floors:
79 uncertain significance, 66 conflicting classifications of pathogenicity, 17 pathogenic/likely pathogenic, 16 likely pathogenic, 12 benign/likely benign, 11 pathogenic, 9 benign, 5 likely benign
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 1034077 | NM_000124.4(ERCC6):c.2093dup (p.Thr699fs) | ERCC6 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 1068941 | NM_000124.4(ERCC6):c.2792_2802del (p.Ile931fs) | ERCC6 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1073323 | NM_000124.4(ERCC6):c.2170-1G>A | ERCC6 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1701 | NM_000124.4(ERCC6):c.2203C>T (p.Arg735Ter) | ERCC6 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 1703 | NM_000124.4(ERCC6):c.1357C>T (p.Arg453Ter) | ERCC6 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 1705 | NM_000124.4(ERCC6):c.1971_1974dup (p.Thr659fs) | ERCC6 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 1711 | NM_000124.4(ERCC6):c.2047C>T (p.Arg683Ter) | ERCC6 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 190147 | NM_000124.4(ERCC6):c.1526+1G>T | ERCC6 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 190150 | NM_000124.4(ERCC6):c.1518del (p.Lys506fs) | ERCC6 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 190160 | NM_000124.4(ERCC6):c.2167C>T (p.Gln723Ter) | ERCC6 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 190162 | NM_000124.4(ERCC6):c.2599-26A>G | ERCC6 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 190163 | NM_000124.4(ERCC6):c.2830-2A>G | ERCC6 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 190167 | NM_000124.4(ERCC6):c.3536del (p.Tyr1179fs) | ERCC6 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 190170 | NM_000124.4(ERCC6):c.3904C>T (p.Gln1302Ter) | ERCC6 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 190171 | NM_000124.4(ERCC6):c.3952_3953del (p.Arg1318fs) | ERCC6 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 2000913 | NM_000124.4(ERCC6):c.1717_1720del (p.Cys573fs) | ERCC6 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 212733 | NM_000124.4(ERCC6):c.466C>T (p.Gln156Ter) | ERCC6 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 225905 | NM_000124.4(ERCC6):c.643G>T (p.Glu215Ter) | ERCC6 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 430298 | NM_000124.4(ERCC6):c.1834C>T (p.Arg612Ter) | ERCC6 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 432341 | NM_000124.4(ERCC6):c.355G>T (p.Glu119Ter) | ERCC6 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 502165 | NM_000124.4(ERCC6):c.2839C>T (p.Arg947Ter) | ERCC6 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 522698 | NM_000124.4(ERCC6):c.2551T>A (p.Trp851Arg) | ERCC6 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 550657 | NM_000124.4(ERCC6):c.2286+1G>A | ERCC6 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 550722 | NM_000124.4(ERCC6):c.1009A>T (p.Lys337Ter) | ERCC6 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 551374 | NM_000124.4(ERCC6):c.2287-2A>G | ERCC6 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 551535 | NM_000124.4(ERCC6):c.61C>T (p.Gln21Ter) | ERCC6 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 556870 | NM_000124.4(ERCC6):c.207dup (p.Pro70fs) | ERCC6 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 835111 | NM_000124.4(ERCC6):c.763A>T (p.Lys255Ter) | ERCC6 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 3595241 | NM_000124.4(ERCC6):c.3656del (p.Gly1219fs) | ERCC6 | Likely pathogenic | criteria provided, single submitter |
| 3595247 | NM_000124.4(ERCC6):c.3539dup (p.His1181fs) | ERCC6 | Likely pathogenic | criteria provided, single submitter |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 0 · Orphanet: 5 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| ERCC6 | Orphanet:1466 | COFS syndrome |
| ERCC6 | Orphanet:178338 | UV-sensitive syndrome |
| ERCC6 | Orphanet:90321 | Cockayne syndrome type 1 |
| ERCC6 | Orphanet:90322 | Cockayne syndrome type 2 |
| ERCC6 | Orphanet:90324 | Cockayne syndrome type 3 |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| ERCC6 | HGNC:3438 | ENSG00000225830 | P0DP91 | Chimeric ERCC6-PGBD3 protein | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| ERCC6 | Chimeric ERCC6-PGBD3 protein | Involved in repair of DNA damage following UV irradiation, acting either in the absence of ERCC6 or synergistically with ERCC6. |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 1 | 1.8× | 0.558 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| ERCC6 | Other/Unknown | no | PGBD, PiggyBac_TE-derived, CC_ERCC-6_N |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| male germ line stem cell (sensu Vertebrata) in testis | 1 |
| oocyte | 1 |
| secondary oocyte | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| ERCC6 | 257 | ubiquitous | marker | oocyte, secondary oocyte, male germ line stem cell (sensu Vertebrata) in testis |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| ERCC6 | 13 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| ERCC6 | P0DP91 | 12 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 7. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 1 | 265.6× | 0.008 | ERCC6 |
| RNA Polymerase I Transcription Initiation | 1 | 223.9× | 0.008 | ERCC6 |
| Formation of TC-NER Pre-Incision Complex | 1 | 211.5× | 0.008 | ERCC6 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | 1 | 178.4× | 0.008 | ERCC6 |
| Dual incision in TC-NER | 1 | 173.0× | 0.008 | ERCC6 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 1 | 152.3× | 0.008 | ERCC6 |
| B-WICH complex positively regulates rRNA expression | 1 | 121.5× | 0.008 | ERCC6 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| positive regulation of peptidyl-serine phosphorylation of STAT protein | 1 | 8426.0× | 0.003 | ERCC6 |
| pyrimidine dimer repair | 1 | 4213.0× | 0.003 | ERCC6 |
| response to superoxide | 1 | 3370.4× | 0.003 | ERCC6 |
| regulation of DNA-templated transcription elongation | 1 | 2808.7× | 0.003 | ERCC6 |
| DNA protection | 1 | 2808.7× | 0.003 | ERCC6 |
| transcription elongation by RNA polymerase I | 1 | 2106.5× | 0.003 | ERCC6 |
| negative regulation of double-strand break repair via nonhomologous end joining | 1 | 2106.5× | 0.003 | ERCC6 |
| response to UV-B | 1 | 1872.4× | 0.003 | ERCC6 |
| double-strand break repair via classical nonhomologous end joining | 1 | 1685.2× | 0.003 | ERCC6 |
| single strand break repair | 1 | 1404.3× | 0.003 | ERCC6 |
| positive regulation of DNA-templated transcription, elongation | 1 | 1296.3× | 0.003 | ERCC6 |
| transcription-coupled nucleotide-excision repair | 1 | 1203.7× | 0.003 | ERCC6 |
| positive regulation of transcription by RNA polymerase III | 1 | 936.2× | 0.003 | ERCC6 |
| response to X-ray | 1 | 887.0× | 0.003 | ERCC6 |
| regulation of transcription elongation by RNA polymerase II | 1 | 802.5× | 0.003 | ERCC6 |
| positive regulation of transcription by RNA polymerase I | 1 | 648.1× | 0.004 | ERCC6 |
| response to gamma radiation | 1 | 581.1× | 0.004 | ERCC6 |
| protein localization to chromatin | 1 | 581.1× | 0.004 | ERCC6 |
| positive regulation of defense response to virus by host | 1 | 526.6× | 0.004 | ERCC6 |
| base-excision repair | 1 | 468.1× | 0.004 | ERCC6 |
| DNA damage checkpoint signaling | 1 | 391.9× | 0.004 | ERCC6 |
| positive regulation of double-strand break repair via homologous recombination | 1 | 383.0× | 0.004 | ERCC6 |
| photoreceptor cell maintenance | 1 | 358.6× | 0.004 | ERCC6 |
| positive regulation of DNA repair | 1 | 358.6× | 0.004 | ERCC6 |
| intrinsic apoptotic signaling pathway in response to DNA damage | 1 | 324.1× | 0.005 | ERCC6 |
| JNK cascade | 1 | 271.8× | 0.005 | ERCC6 |
| positive regulation of transcription initiation by RNA polymerase II | 1 | 271.8× | 0.005 | ERCC6 |
| response to toxic substance | 1 | 210.7× | 0.006 | ERCC6 |
| neurogenesis | 1 | 208.1× | 0.006 | ERCC6 |
| multicellular organism growth | 1 | 137.0× | 0.009 | ERCC6 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| ERCC6 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 1 | ERCC6 |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| ERCC6 | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: ERCC6